Summary

The XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer [TROPIC; NCT00417079] trial showed that treatment with cabazitaxel (CbzP) produced statistically significant improvement in overall survival versus mitoxantrone plus prednisone in patients with metastatic, castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen (HR, 0.70; p<0.0001). This article discusses interim results from a cohort compassionate-use program with CbzP plus prednisone for patients with mCRPC [EAP; NCT01254279; Bavbek SE et al. J Clin Oncol (suppl; asbtr e15112) 2012].